European Medicines Agency validates Marketing Authorization Applications for AbbVie’s investigational, all-oral, interferon-free therapy for the treatment of genotype 1 chronic hepatitis C
17 June 2014 | By AbbVie
AbbVie announced that the Marketing Authorization Applications for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 hepatitis C virus infection have been validated and are under accelerated assessment by the European Medicines Agency...
